ArticleEuropean neurology2026
Perivascular Space Progression in Patients with Cerebral Amyloid Angiopathy.
Article in European neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enlarged Centrum Semiovale Perivascular Spaces as a Noninvasive Imaging Marker of Vascular Amyloid Deposition in Amyloid-Positive Individuals without Cerebral Amyloid Angiopathy-Related Hemorrhages.Dementia and geriatric cognitive disorders extraArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionDilated perivascular spaces (PVS) are associated with small vessel disease in the aging population. We sought to investigate the incidence and dynamic evolution of magnetic resonance imaging (MRI)-detectable PVS progression in patients with cerebral amyloid angiopathy (CAA).
methodsPatients with symptomatic CAA who underwent baseline and follow-up MRI scans >2 years apart were included. The severity of both basal ganglia (BG) and centrum semiovale (CSO) PVS were rated. Multivariable logistic regression was used to determine the risk factors for PVS progression.
resultsWe included 90 patients with CAA (mean age 72.6 years, standard deviation 8.0 years), of which 53 (58.9%) had intracerebral hemorrhage (ICH) at baseline. During a median follow-up of 4.8 years (interquartile range: 3.6-6.6 years), PVS progression was observed in 24 patients (26.7%) at follow-up MRI. After adjusting for age, hypertension, and time between baseline and follow-up MRI, cerebral microbleed (CMB) progression (OR: 4.12, 95% CI: 1.31-12.95; p = 0.015) and presence of ICH at baseline (OR: 8.61, 95% CI: 2.09-35.52; p = 0.003) were independent predictors of PVS progression. In multivariable regression analysis, presence of ICH (OR: 8.78, 95% CI: 1.74-44.35; p = 0.009) and hypertension (OR: 5.73, 95% CI: 1.25-26.29; p = 0.025) were associated with BG-PVS progression. However, only CMB progression (OR: 10.17, 95% CI: 1.84-56.35; p = 0.008) was associated with CSO-PVS progression.
conclusionPVS progression occurs in a subset of CAA patients reimaged after a median of 4.8 years and is associated with CMB progression. PVS progression might be a useful neuroimaging marker for visualizing CAA-related vascular changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.